Artin Bioscience
Denver, US · Founded 2021 · Delaware corporation
Founders & leadership
DD
David DoyleNamed on SEC filing
EE
Erik EgliteNamed on SEC filing
CM
Charles MagolskeNamed on SEC filing
NV
Norbert VoelkelNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$482.5K disclosed across 1 round · 2023
▶$482.5KraisedMar 2023 · PharmaceuticalsRule 506(c)
▶$482.5KraisedMar 2023 · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- David DoyleExecutive Officer, Director
- Erik EgliteExecutive Officer, Director
- Charles MagolskeExecutive Officer, Director
- Norbert VoelkelDirector
- Offering amount
- $482.5K
- Amount sold
- $482.5K
- Minimum investment
- $5K
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Artin Bioscience raised?
- Artin Bioscience has disclosed $482.5K raised across 1 round.
- Where is Artin Bioscience headquartered?
- Artin Bioscience is headquartered in Denver, US.